Brown Advisory
PVLA

Brown Advisory’s Palvella Therapeutics PVLA Stock Holding History

Brown Advisory’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$665K Sell
4,349
-420
-9% -$51K ﹤0.01% 1049
2026
Q1 		$594K Sell
4,769
-1,610
-25% -$168K ﹤0.01% 1010
2025
Q4 		$668K Hold
6,379
– – ﹤0.01% 969
2025
Q3 		$400K Buy
+6,379
New +$284K ﹤0.01% 1110

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Brown Advisory's PVLA Position: Q2 2026 in Review

Brown Advisory reduced its Palvella Therapeutics (PVLA) stake by 8.8% in Q2 2026, selling an estimated $51K and leaving 4,349 shares worth $665K. The position accounts for ﹤0.01% of the portfolio, ranked #1049.

Brown Advisory first reported a position in PVLA in Q3 2025 and has held it in 4 quarters since. The position peaked at $668K in Q4 2025. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Brown Advisory held 4,349 shares of Palvella Therapeutics worth $665K as of Q2 2026.
  • Brown Advisory sold 420 Palvella Therapeutics shares in Q2 2026, an estimated $51K.
  • Palvella Therapeutics made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #1049 holding.
  • Brown Advisory first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Brown Advisory's Palvella Therapeutics position peaked at $668K in Q4 2025.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.